Warfarin cohort (reference) Apixaban cohort Warfarin cohort (reference) Dabigatran cohort Warfarin cohort (reference) Rivaroxaban cohort
N/Mean %/SD N/Mean %/SD STD* N/Mean %/SD N/Mean %/SD STD* N/Mean %/SD N/Mean %/SD STD*
Sample size 18,181 100% 18,181 100% 0 6646 100% 6646 100% 0 22,053 100% 22,053 100% 0
Age† 72.7 8.8 72.8 9.0 1.52 70.9 9.3 70.7 9.1 1.51 72.3 8.9 72.3 8.8 0.21
Gender†
Male 9268 51.0% 9260 50.9% 0.09 3633 54.7% 3632 54.6% 0.03 11,372 51.6% 11,313 51.3% 0.54
US geographic region†
Northeast 3132 17.2% 3137 17.3% 0.07 1264 19.0% 1244 18.7% 0.77 3776 17.1% 3828 17.4% 0.62
Midwest 4588 25.2% 4608 25.3% 0.25 1640 24.7% 1624 24.4% 0.56 6275 28.5% 6174 28.0% 1.02
South 7908 43.5% 7834 43.1% 0.82 2643 39.8% 2724 41.0% 2.48 8560 38.8% 8624 39.1% 0.60
West 2501 13.8% 2553 14.0% 0.83 1073 16.1% 1024 15.4% 2.02 3377 15.3% 3365 15.3% 0.15
Other 52 0.3% 49 0.3% 0.31 26 0.4% 30 0.5% 0.93 65 0.3% 62 0.3% 0.25
Race (only for Humana and Medicare)†
White 13,165 89.0% 13,190 89.2% 0.54 4367 88.8% 4338 88.2% 1.85 15,805 88.9% 15,796 88.9% 0.16
Black 1010 6.8% 981 6.6% 0.78 298 6.1% 324 6.6% 2.17 1158 6.5% 1178 6.6% 0.45
Other 619 4.2% 623 4.2% 0.13 251 5.1% 254 5.2% 0.28 812 4.6% 801 4.5% 0.30
1|2|3|4|5|6|7|8